Tamas Masszi

Professor

Semmelweis University

Hungary

Research Interests

Explore related searches

Professors in Hungary

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (8)

András Gézsi

Budapest University of Technology and Economics

HUNGARY

View details

Wojciech Maciej Legiec

head physician

POLAND

View details

Zoltán Pós

HUNGARY

View details

Norbert Grzasko

Medical University of Lublin

POLAND

View details

Ewa Lech-Maranda

Institute of Hematology and Transfusion Medicine

POLAND

View details

László Gopcsa

HUNGARY

View details

György Sinkovits

Semmelweis University

HUNGARY

View details

András Dávid Tóth

Semmelweis University

HUNGARY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tamas Masszi

Research Interests

Explore related searches

Contact this professor

Articles (10)

Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality

Decreased Plasma Level of Cytokeratin 20 (KRT20) Is Indicative of the Emergence and Severity of Acute GvHD Irrespective to the Type of Organ Involvement

Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study

Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers

Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial

Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection

Final Overall Survival Analysis of the TOURMALINE-MM1 Phase III Trial of Ixazomib, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Health-related quality of life maintained over time in patients with relapsed or refractory multiple myeloma treated with daratumumab in combination with bortezomib and dexamethasone: results from the phase III CASTOR trial

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Long-time progression-free survival in relapsed, refractory multiple myeloma with the oral ixazomib-lenalidomide-dexamethasone regime [Hosszú távú progressziómentes túlélés relabált, refrakter myeloma multiplex tisztán orális ixazomib-lenalidomid-dexametazon kezelésével]

Collaborators (8)

András Gézsi

Wojciech Maciej Legiec

Zoltán Pós

Norbert Grzasko

Ewa Lech-Maranda

László Gopcsa

György Sinkovits

András Dávid Tóth

Make your next move.